Acceptable changes in quality attributes of glycosylated biopharmaceuticals
Top Cited Papers
- 8 April 2011
- journal article
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 29 (4), 310-312
- https://doi.org/10.1038/nbt.1839
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Understanding and circumventing resistance to anticancer monoclonal antibodiesmAbs, 2009
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPharmacology & Therapeutics, 2008
- Mechanisms of killing by anti-CD20 monoclonal antibodiesMolecular Immunology, 2007
- Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector functionJournal of Chromatography B, 2007
- Determination of the origin of the N‐terminal pyro‐glutamate variation in monoclonal antibodies using model peptidesBiotechnology & Bioengineering, 2006
- Characterizing biological products and assessing comparability following manufacturing changesNature Biotechnology, 2004
- Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietinExperimental Hematology, 2003
- Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular ToxicityJournal of Biological Chemistry, 2002
- Development and characterization of novel erythropoiesis stimulating protein (NESP)British Journal of Cancer, 2001